Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × pembrolizumab × NET × Clear all

Phase

Status

Active not recruiting 3 Recruiting 2 Completed 2 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 79 Gastrointestinal 48 Head & Neck 46 Dermatologic 46 Genitourinary 35 Breast 31 Gynecologic 25 Other solid neoplasm 22 Lymphoid 15 Tumor-Agnostic 9 CNS 8 Plasma cell 7 Sarcoma 6 Other hematologic neoplasm 3 Myeloid 2 Endocrine 2 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 6 lutetium Lu 177 dotatate 3 surufatinib 2 lanreotide 2 gallium Ga 68 dotatate 2 dactolisib 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Erlotinib Hydrochloride 2 Capecitabine 2 tislelizumab 1 pertuzumab 1 pembrolizumab 1 fosbretabulin 1 famitinib 1 entinostat 1 arginyllysine 1 amino-acid, glucose, and electrolyte solution 1 Surveys and Questionnaires 1 Somatostatin 1 Serotonin 1 Quality of Life 1 Panobinostat 1 Oxaliplatin 1 Ondansetron 1 Octreotide 1 Nivolumab 1 Leucovorin 1 LY2584702 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03190213 2021-06-22

Pembro NEC

University of Utah

Phase 2 Terminated

6 enrolled 13 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡